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Poster Session I S269Results:HLA-DP (A1 or B1) mismatch compared to DP match did
not affect the incidences of acute graft-versus-host disease (GVHD)
grades II-IV (33% vs. 27%; P5 0.20), or grades III-IV (6% vs. 8%; P
5 0.87). Furthermore, the incidence of chronic GVHD was similar
(28% vs. 27%; P5 0.49), and there was no impact on patient overall
survival using DP mismatched compared to DP matched donors
(55% vs. 50%, P 5 0.72). However, in separate analysis DPA1 mis-
match was associated with decreased overall survival (HR 1.50, P 5
0.02), when compared to matched recipients irrespective of
HLA-DPB1 and HLA-C match. In univariate analysis, HLA-
DPA1 mismatch was associated with increased risk of transplant-
related mortality (P 5 0.04), although incidences of acute and
chronic GVHD were similar. Furthermore, a tendency to an in-
creased risk of infection-related mortality was noted in patients
mismatched for HLA-DPA1 (P 5 0.07).
Conclusions: This study suggests that HLA-DPA1 mismatch is
associated with inferior survival, which may be caused by an in-
creased risk of infection-related mortality. At present there are
few publications available, which investigate the role of DPA1
and DPB1 mismatch separately, and future studies to uncover
the importance of DPA1 and DPB1 compatibility in unrelated
HSCT are warranted.177
ETHNICITY BETWEEN DONOR AND RECIPIENT AFFECTS OVERALL
SURVIVAL IN UMBILICAL CORD BLOOD TRANSPLANTATION
Bachier, C., Cheruku, P.S., Shaughnessy, P., Chan, K., Madden, R.,
Jude, V., LeMaistre, C.F. Texas Transplant Institute, San Antonio, TX
This study retrospectively analyses the effects of ethnicity on
clinical outcomes after UCBT. Patients were transplanted at
the Texas Transplant Institute in San Antonio between 2001
and 2010. CIBMTR and hospital records supplied the data.
Two hundred and sixty patients were evaluated including Whites
(76), Hispanics (141), Blacks (19) and Asians (6). Black and Asians
were excluded from analysis due to small numbers. Age, cell
dose, myeloablative versus non-myeloablative conditioning regi-
mens, single (s) versus double (d) UCBT and the prevalence of
high risk malignancies were similar between the two ethnicities
(Table). More Whites (88%) were transplanted for malignant
diseases than Hispanics (68%) (p\0.001). Incidence of acute
and chronic graft-versus-host disease (GVHD) (Table), overall
survival (OS) (Table), disease related mortality (DRM) and
non-disease related mortality (NDRM) were similar between
Whites (DRM: 20% and NDRM: 23%) and Hispanics (DRM:
16% and NDRM: 24%) and regardless of whether they had ma-
lignant or non-malignant disease, standard or high risk malignant
disease, single or double transplants, and age. Hispanics who re-
ceived an ethnically matched s UCB product had a longer OS
(88.7 months) than Whites (68.5 months) (p 5 0.030) and
a shorter OS (43.3 months) than Whites when each received an
ethnically mismatched s UCB product (p 5 0.004). White and
Hispanics with ethnically matched and mismatched sUCBT
had similar number of patients with malignant and high risk
malignant disease.
Improvement in OS in Hispanics patients with ethnically
matched s UCB products was related to an increase in OS from
transplant related mortalities while worse OS in Hispanics with
ethnically mismatched s UCB products was related to decreases
in OS from both transplant-related and disease-related mortalities.
Cell dose and degree of HLA matching was similar for all patients
and for Whites and Hispanics with ethnically matched and mis-
matched s UCB. There was a trend to shorter OS among all pa-
tients with ethnically matched (82.3 months) versus mismatched
(68.5 months) s UCB. OS was shorter among all Hispanics with
mismatched (43.3 months) than matched (88.7 months) s UCBT
(p 5 0.001).
In conclusion, ethnicmismatches between donor and recipient ap-
pear to affect survival in s UCBT. The effect of ethnic mismatches
was more pronounced in Hispanics than Whites.Table.
Characteristics and Outcomes White HispanicNumber of patients 76 141Median age at transplant, years
(range)9.0 (0.1-79.2) 8.0 (0.1-61.7)Age category<18 61 (82%) 116 (82%)$18 13 (17%) 21 (15%)Median weight, kg (range) 25 (4-111) 26.3 (4-160)Recipient sexmale 43 (57%) 90 (65%)female 31 (41%) 50 (35%)Transplant typesingle 57 (75%) 107 (76%)double 18 (24%) 34 (24%)Recipient CMV statuspostitive 24 (32%) 61 (43%)negative 27 (36%) 41 (29%)*Malignant disease 66(88%) 96 (68%)Ethnicity match for s UCBconcordant 39 (70%) 57 (53%)discordant 10 (18%) 28 (26%)*HLA-matching, single transplants6(6) 14 (25%) 9 (8%)5(6) 28 (56%) 50 (47%)4(6) 13 (23%) 44 (41%)Median cell dosex107 TNC/kg (range) 5.7 (1.5-28.5) 5.6 (1.5-45.5)Median days ANC >500 21 (10-50) 20 (10-100)Median days platelets >20K 51 (24-165) 47 (21-167)Median days platelets >50K 60 (29-137) 49 (24-224)Grade of acute GVHDgrades II - IV 33 (44%) 48 (34%)grades III - IV 11 (15%) 31 (22%)Chronic GVHDlimited 9% 28%extensive 11% 15%Overall survival (months) 70.2 73.7Median follow-up in months (range) 28 (.25-121) 25 (.25-69)*p-value <0.05
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GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER DOUBLE-UNIT CORD
BLOOD TRANSPLANTATION (DCBT) IS ASSOCIATEDWITH UNIQUE CLIN-
ICAL FEATURES INCLUDING A HIGHER INCIDENCE OF GRADE III-IV
ACUTE GVHD (AGVHD) IN CHILDREN
Ponce, D.M.1, Gonzales, A.M.R.1, Lubin,M.N.1, Castro-Malaspina, H.1,
Geralt, S.A.1, Goldberg, J.D.1, Jakubowski, A.A.1, Papadopoulos, E.B.1,
Perales, M.-A.1, van den Brink, M.R.M.1, Young, J.W.1,
Kernan, N.A.2, O’Reilly, R.J.2, Prockop, S.E.2, Scaradavou, A.2,
Stevens, C.E.1, Barker, J.N.1 1Memorial Sloan-Kettering Cancer Center,
NewYork,NY; 2Memorial Sloan-Kettering Cancer Center, NewYork, NY
GVHD is a serious complication and common cause of transplant-
related mortality after DCBT. However, relatively little is known
about DCBT GVHD manifestations, treatment response, and risk
factors. We evaluated 108 DCBT recipients (median 37 years, range
0.9-69) transplanted for high-risk hematologic malignancies with
myeloablative (n5 81) or non-myeloablative (n5 27) conditioning,
4-6/6 HLA-matched grafts, calcineurin-inhibitor/mycophenolate
mofetil, and no ATG. With a median follow-up of 28 months, the
cumulative incidences of day 180 grade II-IV and III-IV aGVHD
were 52% (95%CI:42-62) and 24% (95%CI:15-32), respectively.
The median onset was 40 days (range 14-161), and the gut was
most commonly affected (43/54, 80%). Twenty-five patients with
mainly grade II gut aGVHD were treated with budesonide alone,
26 patients with predominantly grade III-IV aGVHD received sys-
temic corticosteroids, and treatment response was achieved in over
80% by day 56 of therapy. However, 41 patients had active
GVHD after day 100 with the majority (61%) having aGVHD,
particularly of the gut. Classical chronic GVHD was uncommon.
